Article
Proteogenomics of glioblastoma associates molecular patterns with survival
1 Mar 2021
Abstract excerpt
Glioblastoma (GBM) is the most aggressive form of glioma, with poor prognosis exhibited by most patients, and a median survival time of less than 2 years. We assemble a cohort of 87 GBM patients whose survival ranges from less than 3 months and up to 10 years and perform both high-resolution mass spectrometry proteomics and RNA sequencing (RNA-seq). Integrative analysis of protein expression, RNA expression, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
